An observational study in Hypercapnic Respiratory Failure, Pulmonary Disease, Chronic Obstructive and Neuromuscular Diseases, sponsored by The Hospital of Vestfold. Completed at 1 site in Norway. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by The Hospital of Vestfold · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study is an open, prospective, single center clinical observational pilot investigation. The aim is to compare the carbon dioxide values measured by the IscAlert sensor, which is inserted in proximity to the nasal mucosa. The study wants to investigate if the nasal mucosa application and measurements are feasible, what kind of possible complications such a measurement can cause, and if the measurements can be a surrogate marker for systemic carbon dioxide values.
he study is an open, prospective, single center clinical observational pilot investigation including 9 patients and 2 healthy volunteers. The aim is to compare the carbon dioxide values measured by the IscAlert sensor, which is inserted in proximity to the nasal mucosa, with the transcutaneous carbon dioxide values measured at the forehead by a transcutaneous carbon dioxide-monitor, the arterial carbon dioxide measurements performed by blood gas analyses, and carbon dioxide measurements registered with the IscAlert sensor implanted in the muscle of the forearm. The study wants to investigate if the nasal mucosa application and measurements are feasible, what kind of possible complications such a measurement can cause, and if the measurements can be a surrogate marker for systemic carbon dioxide values. The study will include patients with a tendency to hypoventilation, thereby giving rise to a carbon dioxide retention; 3 patients with chronic obstructive pulmonary disease with suspected hypercapnic respiratory failure who are evaluated for non-invasive mask-treatment and long-term oxygen treatment supply if needed. 3 patients with neuromuscular disorders and 3 patients with obesity hypoventilation syndrome who are evaluated for non-invasive mask treatment. The measurements will last for about 8 to 14 hours at night while the patients are sleeping. In addition, the study will also include 2 healthy volunteers as a control group. They will have the equipment mounted on them for about 8 hours during the day in connection with normal office work. Follow up by telephone 7 days +/-2 days after the measurements are finished. The inclusion period is expected to be about 9 months.
74 studies on the registry are indexed under Obesity Hypoventilation Syndrome; 11 are open to participants now.
This study's enrollment of 21 is below the median of 50 across 25 observational studies indexed under Obesity Hypoventilation Syndrome.
Browse Obesity Hypoventilation Syndrome studies →The Hospital of Vestfold is the lead sponsor of 16 studies on the registry; 2 are open to participants now.
Compared within Obesity Hypoventilation Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Respiratory Insufficiency. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Nine patients will be selected consequtive from the hypoventilation assessment planning program at the site. Additionally, two healthy individuals, who have no heart-, lung-, or circulatory diseases, no bleeding disorder, no sleep disorders, and no ties whatsoever to the sponsor (Sensocure AS), will be included as volunteers. Otherwise completely freely chosen by the investigators except they must not have any kind of (direct or indirect) acquaintanceship to the investigators. Eligible subjects will be invited to participate in this clinical investigation. All the subjects will be included at least one day before study procedure starts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The subject must meet all of the following inclusion criteria at the time of enrolment:
EITHER
Either
OR
Healthy volunteers
ALL subjects:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 Chronic obstructive pulmonary disease patients monitored with IscAlert sensor at nasal mucosa for 8-14 hours during the night
Device: IscAlert sensor
3 Neuromuscular disease patients monitored with IscAlert sensor at nasal mucosa for 8-14 hours during the night
Device: IscAlert sensor
3 Obesity hypoventilation syndrome patients monitored with IscAlert sensor at nasal mucosa for 8-14 hours during the night
Device: IscAlert sensor
2 healthy volunteers monitored with IscAlert sensor at nasal mucosa for approximately 8 hours during daytime
Device: IscAlert sensor
Insertion of an IscAlert sensor at the nasal mucosa
Partial pressure (level) of carbon dioxide at the nasal mucosa
Nasal mucosa's partial pressure of carbon dioxide (kPa) during insertion period
Time frame: 14 hours
Bleeding
Amount of blood from insertion site (ml)
Time frame: 7 days
Infection
Infection from insertion site at the discretion of the investigator (yes or no)
Time frame: 7 days
Sinusitis
Developement of sinusitis at the discretion of the investigator (yes or no)
Time frame: 7 days
Ulceration
Developement of ulceration at the nasal mucosa at the discretion of the investigator (yes or no)
Time frame: 7 days
Pain at sensor insertion site
Pain at the insertion site measured by Numeric Rating Scale (0= no pain, 10= maximum pain)
Time frame: 7 days
Muscular temperature level
Muscular temperature level (grade Celsius) during insertion period
Time frame: 14 hours
Nasal temperature level
Nasal temperature level (grade Celsius) during insertion period
Time frame: 14 hours
Temporal temperature level
Temporal temperature level (grade Celsius) during insertion period
Time frame: 14 hours
IscAlert functionality
Number of hours with a well-functioning sensor (giving carbon dioxide- and temperature data)
Time frame: 14 hours
Number of pack-years
Smoking habit; number of pack-years by participants
Time frame: 7 days
Length of sensor implantation time
Length of sensor implantation time during hospitalisation
Time frame: 7 days
Peripheral oxygen saturation
Peripheral oxygen saturation (SpO2)
Time frame: 14 hours
Arterial partial pressure (level) of carbon dioxide
Arterial partial pressure of carbon dioxide (kPa) during insertion period - measured in arterial blood
Time frame: 14 hours
Arterial partial pressure (level) of oxygen
Arterial partial pressure of oxygen (kPa) during insertion period - measured in arterial blood
Time frame: 14 hours
Intramuscular partial pressure (level) of carbon dioxide
Intramuscular partial pressure of carbon dioxide (kPa) during insertion period - measured in the forearm
Time frame: 14 hours
Transcutaneous partial pressure (level) of carbon dioxide
Transcutaneous partial pressure of carbon dioxide (kPa) during insertion period, measured at the skin of the forehead
Time frame: 14 hours
Patient-Reported Outcome Measures 1a - discomfort
Discomfort in the nose - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 14 hours
Patient-Reported Outcome Measures 1b - discomfort
Discomfort in the nose - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 7 days
Patient-Reported Outcome Measures 2a - runny nose
Runny nose - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 14 hours
Patient-Reported Outcome Measures 2b - runny nose
Runny nose - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 7 days
Patient-Reported Outcome Measures 3a - sneezing
Sneezing - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 14 hours
Patient-Reported Outcome Measures 3b - sneezing
Sneezing - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 7 days
Patient-Reported Outcome Measures 3b - Ulceration
Ulceration in the nose mucouse membrane - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 7 days
Patient-Reported Outcome Measures 3a - Ulceration
Ulceration in the nose mucouse membrane - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 14 hours
Patient-Reported Outcome Measures 4a - tenderness
Tenderness in the nose - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 14 hours
Patient-Reported Outcome Measures 4b - tenderness
Tenderness in the nose - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 7 days
Patient-Reported Outcome Measures 5b - bleeding
Bleeding from the nose - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 7 days
Patient-Reported Outcome Measures 5a - bleeding
Bleeding from the nose - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 14 hours
Patient-Reported Outcome Measures 6a - reduced sense of smell
Reduced sense of smell - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 14 hours
Patient-Reported Outcome Measures 6b - reduced sense of smell
Reduced sense of smell - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 7 days
Patient-Reported Outcome Measures 7b - reduced sense of taste
reduced sense of taste - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 7 days
Patient-Reported Outcome Measures 7a - reduced sense of taste
reduced sense of taste - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 14 hours
Patient-Reported Outcome Measures 8a - difficulty sleeping
difficulty sleeping - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 14 hours
Patient-Reported Outcome Measures 8b - easy to wake up while sleeping
easy to wake up while sleeping - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 7 days
Patient-Reported Outcome Measures 9 - problems with eating and drinking
problems with eating and drinking - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 14 hours
Patient-Reported Outcome Measures 10 - difficult breathing
difficult breathing - Patient-Reported Outcome Measure, Scale 1 to 5 (1= no, 2= little, 3=Some, 4=very 5=Extreme)
Time frame: 14 hours
Patient-Reported Outcome Measures 11a - diagnosed infection in the nose or sinuses
diagnosed infection in the nose or sinuses - Patient-Reported Outcome Measure, Scale 1 to 2 (1= No, 2= Yes)
Time frame: 14 hours
Patient-Reported Outcome Measures 11b - diagnosed infection in the nose or sinuses
diagnosed infection in the nose or sinuses - Patient-Reported Outcome Measure, Scale 1 to 2 (1= No, 2= Yes)
Time frame: 7 days
Plan to share: No — No plan to share IPD to other researchers
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Mar 2026, 13 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Obesity Hypoventilation Syndrome →
The Hospital of Vestfold